低分子肝素联合肝素在早孕绒毛膜肿块中的应用价值分析。

IF 2.5 4区 医学 Q2 OBSTETRICS & GYNECOLOGY
International Journal of Women's Health Pub Date : 2025-04-07 eCollection Date: 2025-01-01 DOI:10.2147/IJWH.S507845
Xu-Ting Peng, Zhu-Hua Cai, Jie Shen, Hai-Yan Zhu
{"title":"低分子肝素联合肝素在早孕绒毛膜肿块中的应用价值分析。","authors":"Xu-Ting Peng, Zhu-Hua Cai, Jie Shen, Hai-Yan Zhu","doi":"10.2147/IJWH.S507845","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To explore the application value of low molecular weight heparin combined with heparin in patients with chorionic bump in early pregnancy.</p><p><strong>Methods: </strong>This retrospective study collected 86 cases of patients with early pregnancy complicated by chorionic bump treated in our hospital from January 2020 to February 2022. According to the treatment methods, the patients were divided into the combined treatment group (n=41) and the control group (n=45). Patients in the combined treatment group were treated with oral prednisone combined with low molecular weight heparin injection, while patients in the control group received no additional treatment. The changes and differences in chorionic size, serum hormone levels, and uterine artery blood flow parameters before treatment and at 1 month and 2 months after treatment were compared between the two groups. The pregnancy outcomes and adverse reaction rates were also analyzed.</p><p><strong>Results: </strong>At 1 month and 2 months after treatment, the average size of the chorionic bump in the combined treatment group was significantly smaller than before treatment and the control group (P<0.05). Two months after treatment, the average levels of E2, P, and LH in the combined treatment group were significantly higher, and the average FSH level was significantly lower than those before treatment and in the control group (P<0.05). At 1 month and 2 months after treatment, the average RI in the combined treatment group was significantly lower than before treatment and the control group, and although the average S/D ratio was higher than before treatment, it was still lower than that of the control group (P<0.05). The incidence of adverse pregnancy outcomes in the combined treatment group was significantly lower than that in the control group (χ²/P=5.469/0.019). There was no significant difference in the incidence of adverse reactions between the two groups (χ²/P=0.613/0.434).</p><p><strong>Conclusion: </strong>Prednisone combined with low molecular weight heparin can effectively reduce the size of the chorionic bump, improve uterine artery blood flow parameters, and ultimately lower the risk of adverse pregnancy outcomes in patients with early pregnancy complicated by chorionic bump. This treatment approach has reliable clinical safety and holds potential for broader application in such patients.</p>","PeriodicalId":14356,"journal":{"name":"International Journal of Women's Health","volume":"17 ","pages":"973-982"},"PeriodicalIF":2.5000,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11988196/pdf/","citationCount":"0","resultStr":"{\"title\":\"Analysis of the Application Value of Low Molecular Weight Heparin Combined with Heparin in Patients with Chorionic Bump in Early Pregnancy.\",\"authors\":\"Xu-Ting Peng, Zhu-Hua Cai, Jie Shen, Hai-Yan Zhu\",\"doi\":\"10.2147/IJWH.S507845\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To explore the application value of low molecular weight heparin combined with heparin in patients with chorionic bump in early pregnancy.</p><p><strong>Methods: </strong>This retrospective study collected 86 cases of patients with early pregnancy complicated by chorionic bump treated in our hospital from January 2020 to February 2022. According to the treatment methods, the patients were divided into the combined treatment group (n=41) and the control group (n=45). Patients in the combined treatment group were treated with oral prednisone combined with low molecular weight heparin injection, while patients in the control group received no additional treatment. The changes and differences in chorionic size, serum hormone levels, and uterine artery blood flow parameters before treatment and at 1 month and 2 months after treatment were compared between the two groups. The pregnancy outcomes and adverse reaction rates were also analyzed.</p><p><strong>Results: </strong>At 1 month and 2 months after treatment, the average size of the chorionic bump in the combined treatment group was significantly smaller than before treatment and the control group (P<0.05). Two months after treatment, the average levels of E2, P, and LH in the combined treatment group were significantly higher, and the average FSH level was significantly lower than those before treatment and in the control group (P<0.05). At 1 month and 2 months after treatment, the average RI in the combined treatment group was significantly lower than before treatment and the control group, and although the average S/D ratio was higher than before treatment, it was still lower than that of the control group (P<0.05). The incidence of adverse pregnancy outcomes in the combined treatment group was significantly lower than that in the control group (χ²/P=5.469/0.019). There was no significant difference in the incidence of adverse reactions between the two groups (χ²/P=0.613/0.434).</p><p><strong>Conclusion: </strong>Prednisone combined with low molecular weight heparin can effectively reduce the size of the chorionic bump, improve uterine artery blood flow parameters, and ultimately lower the risk of adverse pregnancy outcomes in patients with early pregnancy complicated by chorionic bump. This treatment approach has reliable clinical safety and holds potential for broader application in such patients.</p>\",\"PeriodicalId\":14356,\"journal\":{\"name\":\"International Journal of Women's Health\",\"volume\":\"17 \",\"pages\":\"973-982\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-04-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11988196/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Women's Health\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/IJWH.S507845\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Women's Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IJWH.S507845","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:探讨低分子肝素联合肝素在早孕绒毛膜肿块患者中的应用价值。方法:回顾性分析2020年1月至2022年2月我院收治的86例早孕合并绒毛膜肿块患者。根据治疗方法将患者分为联合治疗组(n=41)和对照组(n=45)。联合治疗组采用口服强的松联合低分子肝素注射液治疗,对照组不加治疗。比较两组患者治疗前、治疗后1个月、2个月时绒毛膜大小、血清激素水平、子宫动脉血流参数的变化及差异。分析妊娠结局及不良反应发生率。结果:在治疗后1个月和2个月,联合治疗组绒毛膜肿块的平均大小明显小于治疗前和对照组(p结论:强的松联合低分子肝素可有效减小绒毛膜肿块的大小,改善子宫动脉血流参数,最终降低早期妊娠合并绒毛膜肿块患者不良妊娠结局的风险。这种治疗方法具有可靠的临床安全性,在此类患者中具有广泛应用的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Analysis of the Application Value of Low Molecular Weight Heparin Combined with Heparin in Patients with Chorionic Bump in Early Pregnancy.

Objective: To explore the application value of low molecular weight heparin combined with heparin in patients with chorionic bump in early pregnancy.

Methods: This retrospective study collected 86 cases of patients with early pregnancy complicated by chorionic bump treated in our hospital from January 2020 to February 2022. According to the treatment methods, the patients were divided into the combined treatment group (n=41) and the control group (n=45). Patients in the combined treatment group were treated with oral prednisone combined with low molecular weight heparin injection, while patients in the control group received no additional treatment. The changes and differences in chorionic size, serum hormone levels, and uterine artery blood flow parameters before treatment and at 1 month and 2 months after treatment were compared between the two groups. The pregnancy outcomes and adverse reaction rates were also analyzed.

Results: At 1 month and 2 months after treatment, the average size of the chorionic bump in the combined treatment group was significantly smaller than before treatment and the control group (P<0.05). Two months after treatment, the average levels of E2, P, and LH in the combined treatment group were significantly higher, and the average FSH level was significantly lower than those before treatment and in the control group (P<0.05). At 1 month and 2 months after treatment, the average RI in the combined treatment group was significantly lower than before treatment and the control group, and although the average S/D ratio was higher than before treatment, it was still lower than that of the control group (P<0.05). The incidence of adverse pregnancy outcomes in the combined treatment group was significantly lower than that in the control group (χ²/P=5.469/0.019). There was no significant difference in the incidence of adverse reactions between the two groups (χ²/P=0.613/0.434).

Conclusion: Prednisone combined with low molecular weight heparin can effectively reduce the size of the chorionic bump, improve uterine artery blood flow parameters, and ultimately lower the risk of adverse pregnancy outcomes in patients with early pregnancy complicated by chorionic bump. This treatment approach has reliable clinical safety and holds potential for broader application in such patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
International Journal of Women's Health
International Journal of Women's Health OBSTETRICS & GYNECOLOGY-
CiteScore
3.70
自引率
0.00%
发文量
194
审稿时长
16 weeks
期刊介绍: International Journal of Women''s Health is an international, peer-reviewed, open access, online journal. Publishing original research, reports, editorials, reviews and commentaries on all aspects of women''s healthcare including gynecology, obstetrics, and breast cancer. Subject areas include: Chronic conditions including cancers of various organs specific and not specific to women Migraine, headaches, arthritis, osteoporosis Endocrine and autoimmune syndromes - asthma, multiple sclerosis, lupus, diabetes Sexual and reproductive health including fertility patterns and emerging technologies to address infertility Infectious disease with chronic sequelae including HIV/AIDS, HPV, PID, and other STDs Psychological and psychosocial conditions - depression across the life span, substance abuse, domestic violence Health maintenance among aging females - factors affecting the quality of life including physical, social and mental issues Avenues for health promotion and disease prevention across the life span Male vs female incidence comparisons for conditions that affect both genders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信